ReviewFrontiers in immunology2019
Antibody Epitopes of Pneumovirus Fusion Proteins.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 43 citations in OpenAlex.
- Twenty-five years of human metapneumovirus research.Clinical microbiology reviews · 2026Review
- Stabilization of prefusion hMPV F improves manufacturability and protective immunity across hMPV lineages.Virologica Sinica · 2026Article
- Epidemiological characterization and phylogenetic analysis of human metapneumovirus isolated from children in Ningbo, China, 2020-2024.Microbial genomics · 2026Article
- Broadly neutralizing nanobodies target a defined structural pivot site on the RSV fusion protein.EMBO molecular medicine · 2026Article
- The Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights From 25 Project Countries, 2019-2023.Influenza and other respiratory viruses · 2026Article
- Article
- Molecular Evolution of theMicroorganisms · 2026Article
- Resurgence of human metapneumovirus: an overview of past and current trends.Archives of microbiology · 2026Review
- Epidemiological characteristics and whole-genome analysis of respiratory syncytial virus in Jining city from February 2023 to December 2024.Frontiers in microbiology · 2026Article
- Structural basis for childhood antibody recognition of the human metapneumovirus fusion protein.Nature communications · 2025Article
- [Ziresovir: a potent, selective, and oral inhibitor of the respiratory syncytial virus fusion (F) protein].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Structural Basis for Childhood Antibody Recognition of The Human Metapneumovirus Fusion Protein.bioRxiv : the preprint server for biology · 2025Article
- Structural Basis for Postfusion-Specific Binding to the Respiratory Syncytial Virus F Protein by the Canonical Antigenic Site I Antibody 131-2a.ACS infectious diseases · 2025Article
- Using COVID-19 pandemic perturbation to model RSV-hMPV interactions and potential implications under RSV interventions.Nature communications · 2025Article
- Generation of nanobodies against the F protein of respiratory syncytial virus and establishment of an indirect immunofluorescence assay.Microbiology spectrum · 2025Article
- Vaccine Development for Human Pneumoviruses.Vaccines · 2025Review
- The Cumulative Variations of Respiratory Syncytial Virus Fusion Protein (F) in Ten Consecutive Years in China.Infectious disease reports · 2024Article
- Antibody-mediated protection against respiratory syncytial virus in children.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Design of hepadnavirus core protein-based chimeric virus-like particles carrying epitopes from respiratory syncytial virus.NPJ vaccines · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The pneumoviruses respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are two widespread human pathogens that can cause severe disease in the young, the elderly, and the immunocompromised. Despite the discovery of RSV over 60 years ago, and hMPV nearly 20 years ago, there are no approved vaccines for either virus. Antibody-mediated immunity is critical for protection from RSV and hMPV, and, until recently, knowledge of the antibody epitopes on the surface glycoproteins of RSV and hMPV was very limited. However, recent breakthroughs in the recombinant expression and stabilization of pneumovirus fusion proteins have facilitated in-depth characterization of antibody responses and structural epitopes, and have provided an enormous diversity of new monoclonal antibody candidates for therapeutic development. These new data have primarily focused on the RSV F protein, and have led to a wealth of new vaccine candidates in preclinical and clinical trials. In contrast, the major structural antibody epitopes remain unclear for the hMPV F protein. Overall, this review will cover recent advances in characterizing the antigenic sites on the RSV and hMPV F proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.